- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04307667
Microglia Activation in Asthma (MAIA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
First schedule version:
Screening Visit 0: Consent/Eligibility, Pregnancy Test, Vital Signs, Medical History, Concomitant Meds, Allergy Skin Test, Spirometry, Physical Exam, Blood Draw, MRI Simulation, Fraction of exhaled nitric oxide (FeNO)
Screening Visit 0a: Pregnancy Test, Vital Signs, Adverse Events, Concomitant Meds, Spirometry, WLAC, Fraction of exhaled nitric oxide (FeNO)
Visit 1: Pregnancy Test, Vital Signs, Adverse Events, Concomitant Meds, Spirometry, Blood Draw, Sputum Induction, Fraction of exhaled nitric oxide (FeNO), Cognitive Tests, PET/MRI Scan, Questionnaires
Visit 2: Vital Signs, Adverse Events, Concomitant Meds, Spirometry, Physical Exam, WLAC, Blood Draw, Fraction of exhaled nitric oxide (FeNO)
Visit 3: Pregnancy Test, Vital Signs, Adverse Events, Concomitant Meds, Spirometry, Blood Draw, Sputum Induction, Fraction of exhaled nitric oxide (FeNO), Cognitive Tests, PET/MRI Scan, Questionnaires
Visit 4: Adverse Events, Spirometry, Fraction of exhaled nitric oxide (FeNO)
Second schedule version:
Screening Visit 0: Consent/Eligibility, Pregnancy Test, Vital Signs, Medical History, Concomitant Meds, Allergy Skin Test, Spirometry, Physical Exam, Blood Draw, MRI Simulation
Screening Visit 0a: Pregnancy Test, Vital Signs, Adverse Events, Concomitant Meds, Spirometry, WLAC
Visit 1: Pregnancy Test, Vital Signs, Adverse Events, Concomitant Meds, Spirometry, Blood Draw, Sputum Induction, Fraction of exhaled nitric oxide (FeNO), Cognitive Tests, PET/MRI Scan, Questionnaires
Visit 2: Vital Signs, Adverse Events, Concomitant Meds, Spirometry, Physical Exam, WLAC, Blood Draw, Fraction of exhaled nitric oxide (FeNO), Cognitive Tests, PET/MRI Scan, Questionnaires
Visit 3: Vital Signs, Adverse Events, Concomitant Meds, Spirometry, Blood Draw, Sputum Induction, Fraction of exhaled nitric oxide (FeNO)
Visit 4: Adverse Events, Spirometry, Fraction of exhaled nitric oxide (FeNO)
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jane Sachs
- Phone Number: 6088902980
- Email: jfsachs@wisc.edu
Study Contact Backup
- Name: Corrina Frye
- Phone Number: 6088903073
- Email: cfrye@wisc.edu
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53703-2637
- Recruiting
- University of Wisconsin Madison
-
Contact:
- Jane Sachs, MBE, MPH
- Phone Number: 680-890-2960
- Email: jfsachs@wisc.edu
-
Principal Investigator:
- Melissa Rosenkranz, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or female with no health concerns that might affect the outcome of the study
- Physician diagnosis of asthma for at least six months prior to screening (can be determined at the discretion of an asthma/allergy physician member of the study team)
- At least a 20% decrease in forced expiratory volume (FEV1) during the immediate response following inhaled allergen challenge
- FEV1 > 70% at baseline
- Positive immediate skin test for allergies to ragweed, cat dander, or house dust mite (historical data documented within the last 5 years is acceptable)
- Women of child-bearing potential (WCBP) must have a negative urine pregnancy test for human chorionic gonadotropin (hCG) at screening and within 48 hours of the inhaled allergen challenge(s) and the positron emission tomography (PET) scans. WCBP must agree to use a medically-acceptable form of birth control for the duration of the study (medically-acceptable birth control methods can include: abstinence, barrier methods, oral contraceptives, injection contraceptives or skin absorption contraceptives).
- Asthma medications consisting of only inhaled beta-agonists taken as needed or leukotriene inhibitors
- Ability to tolerate a simulated functional magnetic resonance imaging (fMRI) brain scanning session
- In the opinion of the investigator, capable and willing to grant written informed consent and cooperate with study procedures and requirements
- High-affinity TSPO-binding genotype. Mixed (high/low) binding-affinity genotype may be included at principal investigator's (PI) discretion.
Exclusion Criteria:
- Current smoker (defined as more than 0.5 pack per week for the past 6 months and any smoking within two weeks of study procedures) or has a smoking history exceeding 5 pack years within the last 10 years
- Currently receiving immunotherapy
- Not able to withhold medication(s) as outlined by the study
- Use of psychotropic medication that might affect function of neurocircuitry implicated in the investigator's hypotheses at the discretion of the PI or Co-Investigator (Co-I)
- Needle phobia or claustrophobia
- Major health problems such as autoimmune disease, heart disease, uncontrolled hypertension or lung diseases other than asthma. The listed health problems are definitively exclusionary, but decisions regarding major health problems not listed will be based upon the judgment of the investigator.
- Pre-existing chronic infectious disease
- Use of inhaled corticosteroids or oral corticosteroids within 1 month of screening
- Use of an investigational drug within 30 days of entering the study. This criteria will be reviewed on a case by case basis by the principal investigators or co-investigator to determine appropriate washout period. Appropriate wash out period may be greater than 30 days depending on the half-life of the investigational drug. Participants may be eligible for study participation after completing the washout period designated by the PI or Co-I (physician only).
- Any MRI incompatibility as determined by WIMRs most current MRI screening form
- Does not fit in the MRI scanner
- History of a diagnosed Bipolar Disorder, Schizophrenia, or Schizoaffective Disorder
- History of serious head trauma or seizure disorder (can be included at the discretion of the PI or Co-I)
- Unable, in the judgement of the investigator, to comply with directions and/or tolerate the procedures required for participation in this study
- Pregnant or breast-feeding or has a planned pregnancy during the course of the study
- History of positive COVID-19 test (nasal swab or antibody test)
- Have corrected vision and are not able to wear contacts or see sufficiently well to read without glasses or contacts, as glasses will not fit in the PET/MR head coil
- Any other medical condition or disease that would impact subject safety or data integrity in the opinion of the PIs
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of Neuroinflammation measured by TSPO observed via PET scan
Time Frame: up to 9 days
|
The investigators propose that, in subjects with asthma, provocation of airway inflammation activates microglia, indicative of a neuroinflammatory signal.
The hypothesis is that microglial activation will occur following an inhaled allergen challenge, relative to pre-challenge.
Activation of microglia will be measured using positron emission tomography (PET) with the radiotracer [18F]FEPPA, a tracer selective for translocator protein (TSPO) binding, which is elevated in activated microglia.
|
up to 9 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intensity of Airway Response measured by Fraction of exhaled nitric oxide (FeNO) Level
Time Frame: up to 11 days
|
The investigators propose that a more intense airway inflammatory response, created by the inhaled allergen challenge, will be associated with a greater increase in microglial activation.
The hypothesis is that the increase in markers of airway inflammation, such as FeNO will be positively associated with the increase in microglial activation.
Exhaled nitric oxide level will be determined using the Niox VERO instrumentation to measure FeNO.
The test requires the participant to exhale into the mouthpiece of the FeNO measuring instrument for approximately 10 seconds.
|
up to 11 days
|
Intensity of Airway Response measured by Sputum Eosinophil Count
Time Frame: up to 10 days
|
The investigators propose that a more intense airway inflammatory response, created by the inhaled allergen challenge, will be associated with a greater increase in microglial activation.
The hypothesis is that the increase in markers of airway inflammation, such as sputum eosinophil count will be positively associated with the increase in microglial activation.
Sputum induction is a relatively simple, repeatable, and non-invasive method to collect airway secretions and are a highly relevant biological sample to assess airway inflammation.
|
up to 10 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functionality Measured by Statistical Significance of Co-variation between Cognitive Tasks or Self-Report Instruments and Microglial Activation
Time Frame: up to 10 days
|
The investigators propose that a greater increase in microglial activation will be associated with reduced performance on tasks that assess cognitive function and greater psychological symptoms.
The hypothesis is that a greater post-allergen challenge increase in microglial activation will be associated with a decrement in performance, relative to baseline, on measures of memory, attention, or executive function and elevated reports of depressive and anxious symptoms.
The instruments may include the State-Trait Anxiety Inventory, Beck Depression Inventory, Beck Anxiety Inventory, Penn State Worry Questionnaire, Perceived Stress Scale, Stress and Adversity Inventory, Childhood Trauma and Adversity, and Peak Flow Diary (a diary of asthma symptoms recorded daily).
|
up to 10 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Melissa Rosenkranz, Center for Healthy Minds
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-1309
- A483000 (Other Identifier: UW Madison)
- L&S CTR FOR HEALTHY MINDS (Other Identifier: UW Madison)
- 1R01HL123284-01A1 (U.S. NIH Grant/Contract)
- Protocol Version 4/21/2021 (Other Identifier: UW Madison)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on Whole lung antigen challenge (WLAC)
-
University of Wisconsin, MadisonNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...Completed
-
The Cleveland ClinicEnrolling by invitation
-
The University of QueenslandNot yet recruiting
-
Memorial Sloan Kettering Cancer CenterCompletedSynovial Sarcoma | Single or Multiple Lung MetastasesUnited States
-
Azienda Socio Sanitaria Territoriale degli Spedali...Unknown
-
University Hospital, LilleCompletedHemodynamic Monitoring | Fluid ChallengeFrance
-
Sharon RiddlerNational Institute of Allergy and Infectious Diseases (NIAID)Active, not recruitingComparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure (DC-HIV04)HIV InfectionsUnited States
-
International Geriatric Radiotherapy GroupBrigitta G. BaumertUnknownCOVID-19 Pneumonitis
-
Ology BioservicesCompletedInfluenzaSingapore, Austria
-
Jianwu DaiSouthwest Hospital, China; Nanjing Chest HospitalCompleted